NYSE:PRGO

Perrigo - PRGO Stock Forecast, Price & News

$35.87

+0.47 (+1.33%)

(As of 03/31/2023 12:00 AM ET)

Add

Compare

Today's Range: $35.59
▼
$35.90
50-Day Range: $33.31
▼
$38.75
52-Week Range: $30.78
▼
$43.90

Volume: 806,185 shs
Average Volume: 1.21 million shs
Market Capitalization: $4.85 billion

P/E Ratio: N/A
Dividend Yield: 3.04%
Price Target: $48.00

Institutional Ownership

Perrigo MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 33.8% Upside
$48.00 Price Target
Short Interest: Healthy
3.46% of Shares Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -1.93
Upright™ Environmental Score
News Sentiment: 0.31
Based on 7 Articles This Week
Insider Trading: Selling Shares
$619,867 Sold Last Quarter
Proj. Earnings Growth: 17.83%
From $2.58 to $3.04 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.15 out of 5 stars

Medical Sector

17th out of 996 stocks

Pharmaceutical Preparations Industry

5th out of 484 stocks

3.5

Analyst's Opinion

Consensus Rating
Perrigo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $48.00, Perrigo has a forecasted upside of 33.8% from its current price of $35.87.
Amount of Analyst Coverage
Perrigo has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.46% of the outstanding shares of Perrigo have been sold short.
Short Interest Ratio / Days to Cover
Perrigo has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Perrigo has recently decreased by 16.87%, indicating that investor sentiment is improving significantly.

3.3

Dividend Strength

Dividend Yield
Perrigo pays a meaningful dividend of 3.11%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Perrigo has been increasing its dividend for 21 years.
Dividend Sustainability
Based on earnings estimates, Perrigo will have a dividend payout ratio of 35.86% next year. This indicates that Perrigo will be able to sustain or increase its dividend.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Perrigo has received a 41.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Anti-diarrheal and intestinal anti-inflammatory medication (A07)", "Dental floss", "Antifungal medication (D01) ", "Cough and cold medication (R05)", and "Toothbrushes" products. See details.
Environmental Sustainability
The Environmental Impact score for Perrigo is -1.93.

1.8

News and Social Media Coverage

News Sentiment
Perrigo has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Perrigo this week, compared to 4 articles on an average week.
MarketBeat Follows
Only 2 people have added Perrigo to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Perrigo insiders have sold 225.82% more of their company's stock than they have bought. Specifically, they have bought $190,250.00 in company stock and sold $619,867.00 in company stock.
Percentage Held by Insiders
Only 0.80% of the stock of Perrigo is held by insiders.
Percentage Held by Institutions
94.09% of the stock of Perrigo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Perrigo are expected to grow by 17.83% in the coming year, from $2.58 to $3.04 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Perrigo is -37.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Perrigo is -37.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Perrigo has a P/B Ratio of 1.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Perrigo (NYSE:PRGO) Stock

Perrigo Co. Plc engages in the provision of self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the following segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The CSCI segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Receive PRGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perrigo and its competitors with MarketBeat's FREE daily newsletter.

PRGO Stock News Headlines

March 28, 2023 | finance.yahoo.com

Perrigo Announces New Date for Joint FDA Advisory Committee Meeting to Review Opill® Daily Oral Contraceptive for OTC Use

March 28, 2023 | finance.yahoo.com

U.S. FDA panel to discuss Perrigo's daily OTC birth-control pill in May

April 2, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

March 28, 2023 | seekingalpha.com

Perrigo unit to face FDA AdCom meeting in May for OTC birth control pill

March 21, 2023 | finance.yahoo.com

More Baby-Formula Issues: This Big Brand Is Being Recalled Now

March 20, 2023 | finance.yahoo.com

Some Gerber Baby Formula Recalled Due to Possible Contamination

March 10, 2023 | benzinga.com

Insiders Selling Perrigo And 3 Other Stocks

March 7, 2023 | seekingalpha.com

Perrigo a new buy at Canaccord Genuity with focus on self-care products, cost savings

April 2, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

March 6, 2023 | markets.businessinsider.com

Raymond James Reaffirms Their Buy Rating on Perrigo Company (PRGO)

March 2, 2023 | finance.yahoo.com

Perrigo to Present at Upcoming 12th Annual UBS Global Consumer and Retail Conference

March 1, 2023 | finance.yahoo.com

Perrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil® Dual Action Tablets

February 28, 2023 | finance.yahoo.com

Perrigo Launches its 3-Year Optimize and Accelerate Strategic Plan, Issues Fiscal 2023 Guidance and Introduces 2025 Financial Targets at Investor Day

February 28, 2023 | finance.yahoo.com

Perrigo (PRGO) Tops Q4 Earnings Estimates

February 27, 2023 | finance.yahoo.com

Perrigo Reports Fourth Quarter & Fiscal Year 2022 Financial Results From Continuing Operations

February 21, 2023 | finance.yahoo.com

Perrigo Increases its Quarterly Dividend

February 21, 2023 | finance.yahoo.com

Perrigo raises quarterly dividend by 5% to 27.30 cents a share

February 20, 2023 | finance.yahoo.com

Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?

February 14, 2023 | finance.yahoo.com

Perrigo to Release Fourth Quarter and Fiscal Year 2022 Financial Results on February 27, 2023, Conduct Virtual Investor Day on February 28, 2023

December 26, 2022 | thestreet.com

Perrigo (PRGO) Stock Plunging on Failed Mylan Deal

December 19, 2022 | finance.yahoo.com

Perrigo to Host Virtual Investor Day on February 28, 2023

December 16, 2022 | finance.yahoo.com

SWEDEN’S SKINCARE SENSATION ACO EXTENDS PRESENCE INTO US TIMED TO THE HOLIDAY SEASON

December 16, 2022 | investing.com

Perrigo Co. PT Lowered to $45 at JPMorgan

December 1, 2022 | finance.yahoo.com

Reckitt Benckiser expects baby formula shortage to continue into spring 2023

November 10, 2022 | finance.yahoo.com

‘Long-term investors should turn back toward stocks’: J.P. Morgan says inflation has peaked and suggests 2 stocks to buy

November 8, 2022 | finance.yahoo.com

Why Perrigo Stock Tanked on Tuesday

November 8, 2022 | finance.yahoo.com

Perrigo Shares Fall As Investors React To Lowered FY22 Profit Guidance

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PRGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perrigo and its competitors with MarketBeat's FREE daily newsletter.

PRGO Company Calendar

Last Earnings: 2/27/2023
Ex-Dividend for 3/28 Dividend: 3/09/2023
Dividend Payable: 3/28/2023
Today: 4/02/2023
Next Earnings (Estimated): 5/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:PRGO
CUSIP: 71429010
CIK: 1585364
Web: www.perrigo.com
Phone: (531) 709-4000
Fax: 269-673-9128
Employees: 8,900
Year Founded: 1887

Price Target and Rating

Average Stock Price Forecast: $48.00
High Stock Price Forecast: $54.00
Low Stock Price Forecast: $43.00
Forecasted Upside/Downside: +33.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 13.90
P/E Growth: N/A
Net Income: $-140,600,000.00
Net Margins: -2.91%
Pretax Margin: -3.12%
Return on Equity: 5.79%
Return on Assets: 2.61%

Debt

Debt-to-Equity Ratio: 0.84
Current Ratio: 2.44
Quick Ratio: 1.41

Sales & Book Value

Annual Sales: $4.45 billion
Price / Sales: 1.09
Cash Flow: $4.70 per share
Price / Cash Flow: 7.64
Book Value: $35.96 per share
Price / Book: 1.00

Miscellaneous

Outstanding Shares: 135,110,000
Free Float: 134,028,000
Market Cap: $4.85 billion
Optionable: Optionable
Beta: 0.79

Social Links

Key Executives

Murray S. Kessler
President, Chief Executive Officer & Director

Ronald C. Janish
Executive VP-Global Operations and Supply Chain

Eduardo Guarita Bezerra
Chief Financial Officer & Executive Vice President

Thomas M. Farrington
Chief Information Officer & Executive VP

Grainne Quinn
Chief Medical Officer & Executive Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRGO Stock - Frequently Asked Questions

Should I buy or sell Perrigo stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRGO shares.
View PRGO analyst ratings or view top-rated stocks.
What is Perrigo's stock price forecast for 2023?: 4 brokers have issued 12 month price targets for Perrigo's shares. Their PRGO share price forecasts range from $43.00 to $54.00. On average, they predict the company's stock price to reach $48.00 in the next year. This suggests a possible upside of 33.8% from the stock's current price.
View analysts price targets for PRGO or view top-rated stocks among Wall Street analysts.
How have PRGO shares performed in 2023?: Perrigo's stock was trading at $34.09 on January 1st, 2023. Since then, PRGO shares have increased by 5.2% and is now trading at $35.87.
View the best growth stocks for 2023 here.
Are investors shorting Perrigo?: Perrigo saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 4,680,000 shares, a drop of 16.9% from the February 28th total of 5,630,000 shares. Based on an average daily volume of 1,170,000 shares, the days-to-cover ratio is presently 4.0 days.
View Perrigo's Short Interest.
When is Perrigo's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our PRGO earnings forecast.
How were Perrigo's earnings last quarter?: Perrigo Company plc (NYSE:PRGO) issued its earnings results on Monday, February, 27th. The company reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.70 by $0.05. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.20 billion. Perrigo had a positive trailing twelve-month return on equity of 5.79% and a negative net margin of 2.91%. The firm's revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.60 EPS.
How often does Perrigo pay dividends? What is the dividend yield for Perrigo?: Perrigo announced a quarterly dividend on Tuesday, February 21st. Stockholders of record on Friday, March 10th will be paid a dividend of $0.273 per share on Tuesday, March 28th. This represents a $1.09 annualized dividend and a yield of 3.04%. The ex-dividend date is Thursday, March 9th. This is a boost from the stock's previous quarterly dividend of $0.26.
Read our dividend analysis for PRGO.
What ETFs hold Perrigo's stock?: ETFs with the largest weight of Perrigo (NYSE:PRGO) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco Dynamic Pharmaceuticals ETF (PJP), AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF (SMIG), iShares U.S. Pharmaceuticals ETF (IHE), First Trust Nasdaq Pharmaceuticals ETF (FTXH), ProShares S&P MidCap 400 Dividend Aristocrats ETF (REGL) and VanEck Pharmaceutical ETF (PPH).
Is Perrigo a good dividend stock?: Perrigo (NYSE:PRGO) pays an annual dividend of $1.09 per share and currently has a dividend yield of 3.11%.
Read our dividend analysis for PRGO.

What guidance has Perrigo issued on next quarter's earnings?: Perrigo updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of $2.50-$2.70 for the period, compared to the consensus EPS estimate of $2.78. The company issued revenue guidance of $4.76 billion-$4.94 billion, compared to the consensus revenue estimate of $4.80 billion.
What is Murray S. Kessler's approval rating as Perrigo's CEO?: 38 employees have rated Perrigo Chief Executive Officer Murray S. Kessler on Glassdoor.com. Murray S. Kessler has an approval rating of 83% among the company's employees.
What other stocks do shareholders of Perrigo own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Perrigo investors own include Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Mylan (MYL), AbbVie (ABBV), Allergan (AGN), Intel (INTC), Johnson & Johnson (JNJ), Netflix (NFLX), QUALCOMM (QCOM) and Amgen (AMGN).
What is Perrigo's stock symbol?: Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."
How do I buy shares of Perrigo?: Shares of PRGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Perrigo's stock price today?: One share of PRGO stock can currently be purchased for approximately $35.87.
How much money does Perrigo make?: Perrigo (NYSE:PRGO) has a market capitalization of $4.85 billion and generates $4.45 billion in revenue each year. The company earns $-140,600,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis.
How many employees does Perrigo have?: The company employs 8,900 workers across the globe.
Does Perrigo have any subsidiaries?: The following companies are subsidiares of Perrigo: 010414 UK Limited, 251211 UK Limited, Abtei Omega Pharma GmbH, Aco Hud Nordic AB, Adriatic BST Trgovina in Storitve D.o.o., Adriatic Distribution doo Beograd, Agis Industries, Algorithmics Risk Management Limited, Arginet Investments and Property (2003) Ltd., Athena Neurosciences LLC, Aurora Pharmaceuticals Pty Ltd, Biover NV, Blue Wolf Global Limited, Bluewolf International Limited, Brunel Healthcare Manufacturing Limited, CP Kayak Holdings Inc., CanNegev Ltd, Chefaro Ireland Designated Activity Company, Cinetic Laboratories Argentina SA, Cleversafe UK Limited, Cosmediet - Biotechnie SAS, Despharma Kft., Elan Corporation, Elan Europa Finance S.á r.l., Elan International Services Limited, Elan Pharmaceuticals LLC, Fera Pharmaceuticals, Galpharm Healthcare Limited, Galpharm International, Galpharm International Limited, Geiss Destin & Dunn, Gelcaps Exportadora de Mexico S.A. de C.V., Gr8ness LLC, HRA Pharma, Habsont Unlimited Company, Heartbeat Experts Limited, IBM GF international Treasury Company, IBM International Treasury Services Unlimited Company, IBM Netherlands Treasury B.V., Interdelta S.A., International Business Machines Limited, Irish Biosciences Venture Capital Fund, JB Laboratories, JLR Pharma S.A., Jaico R.D.P. NV, Jewel Consumer Care Pvt. Ltd., Kazmira LLC, Kenexa Global Recruitment Services Limited, Kenexa Quorum Holdings Limited, Kenexa Technology LLC, Kiteacre Limited, L. Perrigo Company, Laboratoire de la Mer SAS, Laboratoires Omega Pharma France SAS, Laboratorios DIBA S.A., Laboratorios Diba, Luxembourg Investment Company 289 Sàrl, MH (UK) Limited, Medgenix Benelux NV, Monksland Holdings B.V., Naturwohl Pharma GmbH, ORION Laboratories, Oce Bio BV, Oce-Bio Nederland B.V., Omega Alpharm Cyprus Ltd., Omega Pharma, Omega Pharma AS, Omega Pharma Australia Pty Ltd, Omega Pharma Austria Healthcare GmbH, Omega Pharma Baltics SIA, Omega Pharma Belgium NV, Omega Pharma Capital NV, Omega Pharma Deutschland GmbH, Omega Pharma GmbH, Omega Pharma Hellas SA Health and Beauty Products, Omega Pharma Hungary Kft., Omega Pharma Innovation & Development NV, Omega Pharma International NV, Omega Pharma Limited, Omega Pharma Luxembourg SarL, Omega Pharma Manufacturing GmbH & Co. KG, Omega Pharma Manufacturing Verwaltungs GmbH, Omega Pharma Nederland B.V., Omega Pharma Trading NV, Omega Pharma s.r.o., Omega Teknika Designated Activity Company, OmegaLabs (Pty) Ltd, Oniqua Europe Limited, Optevia Limited, Orion Laboratories (NZ) Ltd., Orion Laboratories PTY Limited, P-Direct NL B.V., P2C Inc., PBM Canada Holdings LLC, PBM China Holdings LLC, PBM Foods LLC, PBM Holdings LLC, PBM International Holdings LLC, PBM Mexico Holdings LLC, PBM Nutritionals LLC, PBM Products, PBM Products LLC, PBM Products Mexico S de R.L. de C.V., PMI Branded Pharmaceuticals Inc., Paddock Laboratories, Paracelsia Pharma GmbH, Perrigo Asia Holding Company Ltd., Perrigo Australian Holding Company II PTY Limited, Perrigo Bulgaria OOD, Perrigo China Business Trust, Perrigo China Business Trustee LLC, Perrigo Company, Perrigo Company Charitable Foundation, Perrigo Company of Tennessee, Perrigo Company plc, Perrigo Corporation Designated Activity Company, Perrigo Danmark A/S, Perrigo Diabetes Care LLC, Perrigo Direct Inc., Perrigo España SA, Perrigo Europe Invest NV, Perrigo Finance (US) LLC, Perrigo Finance Unlimited Company, Perrigo Florida Inc., Perrigo France SAS, Perrigo Global Holdings Inc., Perrigo Holding NV, Perrigo Holdings Unlimited Company, Perrigo International Finance Designated Activity Company, Perrigo International Holdings II Inc., Perrigo International Holdings LLC, Perrigo International Inc., Perrigo International Insurance Limited, Perrigo Ireland 1 Designated Activity Company, Perrigo Ireland 10 Unlimited Company, Perrigo Ireland 11 DAC, Perrigo Ireland 12 Designated Activity Company, Perrigo Ireland 13 Designated Activity Company, Perrigo Ireland 2 Designated Activity Company, Perrigo Ireland 3 Designated Activity Company, Perrigo Ireland 4 Unlimited Company, Perrigo Ireland 5 Unlimited Company, Perrigo Ireland 6 Unlimited Company, Perrigo Ireland 7 Designated Activity Company, Perrigo Ireland 8 Designated Activity Company, Perrigo Ireland 9 Unlimited Company, Perrigo Ireland Holding Company B.V., Perrigo Ireland Management Designated Activity Company, Perrigo Israel Enterprises & Investments Ltd., Perrigo Israel Holdings II B.V., Perrigo Israel Opportunities II Ltd., Perrigo Israel Trading Limited Partnership, Perrigo Italia S.r.l, Perrigo Kişisel Bakım Ürünleri Sanayi ve Ticaret Limited Şirketi, Perrigo LLC, Perrigo Laboratories India Private Limited, Perrigo Management Company, Perrigo Mexico Holding S.A. de C.V., Perrigo Mexico Investment Holdings LLC, Perrigo Netherlands B.V., Perrigo Netherlands Finco 1 Coöperatief U.A., Perrigo Netherlands Finco 2 B.V., Perrigo Netherlands International Partnership C.V., Perrigo New York Inc., Perrigo Norge AS, Perrigo Oral Health Care Holdings Inc., Perrigo Pharma Holding Nederland BV, Perrigo Pharma International Designated Activity Company, Perrigo Pharma Limited, Perrigo Poland Sp.z.o.o, Perrigo Portugal LDA, Perrigo Research & Development Company, Perrigo România S.R.L., Perrigo Sales Corporation, Perrigo Science Eight Unlimited Company, Perrigo Science One Designated Activity Company, Perrigo Suomi Oy, Perrigo Sverige AB, Perrigo Trading (Shanghai) Co. Ltd., Perrigo UK Acquisition Limited, Perrigo UK Finco Limited Partnership, Perrigo Ukraine LLC, Perrigo Ventures Limited Partnership, Perrigo de Mexico S.A. de C.V., Perrigo do Brasil Farmaceutica Ltda., Pharma Clal (1983) Ltd., Promontory Financial Group (UK) Limited, Quimica y Farmacia S.A. de C.V., Ranir, Ranir (Holdings) Limited, Ranir Changshu Oral Care CO. Ltd., Ranir Global Holdings LLC, Ranir LLC, Ranir Limited, Resilient Systems Europe Limited, Richard Bittner AG, Rosemont Pharmaceuticals, Rubicon Healthcare Holdings Pty Ltd, SPSS Limited, Samenwerkende Apothekers Nederland B.V., ScarAway, Silverpop Systems Limited, Simpler Consulting Limited, Solent Dental Company Limited, Solent Oral Care Limited, Sterling Commerce (UK) Limited, The Analytic Sciences Corporation Limited, The Learning Pharmacy Limited, The Weather Channel Global Media Limited, Totalcare International Corp, Transitive Corporation Limited, Transitive Limited, Truven Health Analytics UK Limited, Velcera, Weather Services International Limited, Wrafton Laboratories, Wrafton Laboratories Limited, Zibo Xinhua - Perrigo Pharmaceutical Company Ltd., i2 Holdings Limited, i2 Intermediate Holdings Limited, and i2 Limited.
Read More
How can I contact Perrigo?: Perrigo's mailing address is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. The official website for the company is www.perrigo.com. The company can be reached via phone at (531) 709-4000, via email at bradley.joseph@perrigo.com, or via fax at 269-673-9128.

This page (NYSE:PRGO) was last updated on 4/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Perrigo - PRGO Stock Forecast, Price & News

Perrigo MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Perrigo (NYSE:PRGO) Stock

PRGO Stock News Headlines

PRGO Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

PRGO Stock - Frequently Asked Questions

Overall MarketRank^™